Structure-guided fragment-based drug discovery at the synchrotron: screening binding sites and correlations with hotspot mapping

Abstract

Structure-guided drug discovery emerged in the 1970s and 1980s, stimulated by the three-dimensional structures of protein targets that became available, mainly through X-ray crystal structure analysis, assisted by the development of synchrotron radiation sources. Structures of known drugs or inhibitors were used to guide the development of leads. The growth of high-throughput screening during the late 1980s and the early 1990s in the pharmaceutical industry of chemical libraries of hundreds of thousands of compounds of molecular weight of approximately 500 Da was impressive but still explored only a tiny fraction of the chemical space of the predicted 10 40 drug-like compounds. The use of fragments with molecular weights less than 300 Da in drug discovery not only decreased the chemical space needing exploration but also increased promiscuity in binding targets. Here we discuss advances in X-ray fragment screening and the challenge of identifying sites where fragments not only bind but can be chemically elaborated while retaining their positions and binding modes. We first describe the analysis of fragment binding using conventional X-ray difference Fourier techniques, with Mycobacterium abscessus SAICAR synthetase (PurC) as an example. We observe that all fragments occupy positions predicted by computational hotspot mapping. We compare this with fragment screening at Diamond Synchrotron Light Source XChem facility using PanDDA software, which identifies many more fragment hits, only some of which bind to the predicted hotspots. Many low occupancy sites identified may not support elaboration to give adequate ligand affinity, although they will likely be useful in drug discovery as ‘warm spots’ for guiding elaboration of fragments bound at hotspots. We discuss implications of these observations for fragment screening at the synchrotron sources. This article is part of the theme issue ‘Fifty years of synchrotron science: achievements and opportunities’.

Ligand‐centered assessment of SARS‐CoV‐2 drug target models in the Protein Data Bank

“…Appropriate validation thus allows the user of such models to make an informed decision whether the model can be useful—or not—for a specific purpose. In the case of small‐molecule ligands complexed with macromolecules of interest, the goal is often identification of lead compounds [2], or in later stages, structure‐guided lead optimization [32]. Experimentally determined ligand structures are also used to train and evaluate docking and virtual ligand screening algorithms [33].…”

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

“…We therefore applied a different approach to M pro , using fragment screening by high-throughput structural biology 22 . Fragment methods have become a staple of modern drug discovery 23 , using small collections (100 s or 1000 s) of small compounds (<300 Da) that bind promiscuously and thus sample a far larger chemical space than is achieved by HTS.…”

Reaction Initiation in Enzyme Crystals by Diffusion of Substrate

“…As schematically illustrated in Figure 7, multiple compounds, which can either be small chemicals, drugs, or drug fragments, can be mixed with microcrystals one by one. With this, highly efficient fragment screening [75] becomes conceivable as a tool for structure based drug design. As the collection of a dataset only takes a few minutes at the EuXFEL, hundreds of compounds can be investigated within a shift by subsequently applying them through a simple T-junction (Figures 2a and 7).…”